Pheton (NASDAQ:PTHL) versus BioNexus Gene Lab (NASDAQ:BGLC) Critical Survey

BioNexus Gene Lab (NASDAQ:BGLC) and Pheton (NASDAQ:PTHL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Valuation & Earnings

This table compares BioNexus Gene Lab and Pheton”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$7.43 million	0.67	-$2.98 million	($1.48)	-1.38
Pheton	$305,215.00	6.49	-$660,000.00	N/A	N/A

Pheton has lower revenue, but higher earnings than BioNexus Gene Lab.

Risk and Volatility

BioNexus Gene Lab has a beta of 4.08, suggesting that its share price is 308% more volatile than the S&P 500. Comparatively, Pheton has a beta of 5.4, suggesting that its share price is 440% more volatile than the S&P 500.

Profitability

This table compares BioNexus Gene Lab and Pheton’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%
Pheton	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations and price targets for BioNexus Gene Lab and Pheton, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	1	0	0	0	1.00
Pheton	1	0	0	0	1.00

Institutional and Insider Ownership

18.9% of BioNexus Gene Lab shares are owned by institutional investors. 0.1% of BioNexus Gene Lab shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Pheton beats BioNexus Gene Lab on 6 of the 9 factors compared between the two stocks.

About BioNexus Gene Lab

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

About Pheton

Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded in 1998 and is headquartered in Beijing, China.